"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 2 | 4 |
| 1994 | 3 | 3 | 6 |
| 1995 | 3 | 3 | 6 |
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 3 | 4 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 3 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 2 | 5 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS). Neurourol Urodyn. 2023 Mar; 42(3):615-622.
-
Chemistry and Function of Glycosaminoglycans in the Nervous System. Adv Neurobiol. 2023; 29:117-162.
-
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022 12 22; 140(25):2722-2729.
-
Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis. Anesth Analg. 2022 05 01; 134(5):1028-1034.
-
Variation in donation after circulatory death hospital policies in a single donor service area. Am J Surg. 2022 07; 224(1 Pt B):595-601.
-
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol. 2022 05; 97(5):519-526.
-
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 10 14; 375:n2400.
-
Cardiac Surgery in a Patient With Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia. J Cardiothorac Vasc Anesth. 2022 04; 36(4):1196-1206.
-
Successful HeartMate 3 LVAD implantation in a patient with active heparin-induced thrombocytopaenia with thrombosis using pre-implantation plasmapheresis and intraoperative continuous prostacyclin. Interact Cardiovasc Thorac Surg. 2021 06 28; 33(1):161-162.
-
The use of enoxaparin as bridge to therapeutic INR after LVAD implantation. J Cardiothorac Surg. 2020 Nov 14; 15(1):329.